Fifth Third Bancorp Sells 171 Shares of Novo Nordisk A/S (NYSE:NVO)

Fifth Third Bancorp lessened its stake in shares of Novo Nordisk A/S (NYSE:NVO) by 0.4% during the 4th quarter, HoldingsChannel.com reports. The institutional investor owned 48,243 shares of the company’s stock after selling 171 shares during the quarter. Fifth Third Bancorp’s holdings in Novo Nordisk A/S were worth $4,150,000 at the end of the most recent quarter.

A number of other institutional investors also recently bought and sold shares of the stock. Xponance Inc. boosted its stake in shares of Novo Nordisk A/S by 27.6% during the 2nd quarter. Xponance Inc. now owns 2,665 shares of the company’s stock worth $380,000 after purchasing an additional 576 shares during the period. AQR Capital Management LLC boosted its position in shares of Novo Nordisk A/S by 110.5% during the second quarter. AQR Capital Management LLC now owns 17,164 shares of the company’s stock valued at $2,450,000 after buying an additional 9,012 shares during the period. The Manufacturers Life Insurance Company grew its stake in shares of Novo Nordisk A/S by 2.2% during the second quarter. The Manufacturers Life Insurance Company now owns 131,876 shares of the company’s stock valued at $18,824,000 after buying an additional 2,817 shares during the last quarter. Scientech Research LLC bought a new stake in shares of Novo Nordisk A/S during the 2nd quarter worth approximately $467,000. Finally, Ascent Group LLC boosted its holdings in Novo Nordisk A/S by 19.1% during the 2nd quarter. Ascent Group LLC now owns 22,869 shares of the company’s stock valued at $3,264,000 after acquiring an additional 3,670 shares during the period. 11.54% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

Several analysts have recently weighed in on NVO shares. StockNews.com downgraded Novo Nordisk A/S from a “strong-buy” rating to a “buy” rating in a research report on Sunday, December 29th. BNP Paribas upgraded shares of Novo Nordisk A/S to a “strong-buy” rating in a research note on Monday, December 2nd. BMO Capital Markets decreased their price target on shares of Novo Nordisk A/S from $156.00 to $105.00 and set an “outperform” rating for the company in a research note on Monday, December 23rd. UBS Group raised Novo Nordisk A/S from a “sell” rating to a “buy” rating in a research note on Wednesday, January 8th. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating and set a $160.00 target price on shares of Novo Nordisk A/S in a research report on Wednesday, November 6th. One equities research analyst has rated the stock with a hold rating, six have given a buy rating and one has given a strong buy rating to the company. According to MarketBeat.com, the company presently has an average rating of “Buy” and an average price target of $145.25.

Novo Nordisk A/S Stock Up 8.4 %

Novo Nordisk A/S stock opened at $87.94 on Monday. The company has a quick ratio of 0.75, a current ratio of 0.94 and a debt-to-equity ratio of 0.43. The firm has a market cap of $394.65 billion, a P/E ratio of 28.46, a P/E/G ratio of 0.90 and a beta of 0.45. The business has a fifty day moving average of $95.35 and a two-hundred day moving average of $114.99. Novo Nordisk A/S has a twelve month low of $78.17 and a twelve month high of $148.15.

About Novo Nordisk A/S

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.